Nicorandil, a selective
mitochondrial K(ATP) channel opener, reinstates the waned protection after multiple cycles of preconditioning. In this study, we determined the signal transduction activated in heart after 3 or 8 cycles of preconditioning and prolonged
ischemia in rabbits treated with placebo or
nicorandil. In a first series (eight groups) we evaluated the (%)
infarct to risk ratio after 30 min
ischemia/3 h reperfusion and in a second series (six groups), we assessed the intracellular levels of
cyclic GMP (c-GMP),
protein kinase C (PKC) activity and p38-mitogen activated
protein kinase (p38-MAPK) phosphorylation from heart samples taken during the long
ischemia. Cardioprotection by 3 cycles of preconditioning (11.7+/-3.8% vs 45.9+/-5.2% in the control, P<0.001) was lost after 8 cycles (43.9+/-5.1%, P=NS vs control).
Nicorandil restored it to the levels of classic preconditioning (13.7+/-2.4% vs 40.8+/-3.5% in respective controls, P<0.001). This was reversed by the p38-MAPK inhibitor
SB203580 (48.8+/-5.1%) which had no protective effect in the control group (44.6+/-5.8%). In the placebo-treated rabbits, intracellular c-GMP and PKC were increased only in the group subjected to 3 cycles of preconditioning. Despite that
nicorandil equalizes the intracellular levels of c-GMP, PKC and activated p38-MAPK at the long
ischemia, specific alterations of p38-MAPK phosphorylation differentiate the protected groups. Our data delineate the signal transduction mechanism mediating the beneficial effect of
nicorandil and imply that the recapture of the lost protection is due to a dynamic process of the intracellular mediators accompanied by an increase in p38-MAPK phosphorylation and not to an instantaneous event.